Thyroid cancer
Conditions
Interventions
Experimental group:Dexmedetomidine Intravenous Pump Infusion
Control Group:Normal Saline Placebo Intravenous Pump Infusion
Sponsors
The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with thyroid cancer confirmed by clinical imaging and pathological biopsy, scheduled for elective unilateral or bilateral thyroidectomy? combined with central neck dissection. 2.Aged between 18 and 65 years, inclusive; gender not restricted. 3.American Society of Anesthesiologists (ASA)? physical status classification I–III, with no severe underlying diseases and with cardiac, pulmonary, hepatic, and renal functions essentially within normal limits. 4.Preoperative laryngeal examination confirming normal vocal cord mobility and intact recurrent laryngeal nerve (RLN)? function, with no history of hoarseness or throat disorders. 5.No history of allergy to anesthetic agents and no contraindications to the use of dexmedetomidine. 6.Voluntary participation in the study, provision of signed informed consent, and good compliance anticipated.
Exclusion criteria
Exclusion criteria: 1.History of previous cervical surgery or radiotherapy, or presence of congenital/anatomical abnormalities of the neck. 2.Pre-existing recurrent laryngeal nerve injury, vocal cord paralysis, or hoarseness. 3.Severe cardiovascular or cerebrovascular disease, hepatic or renal failure, or coagulation dysfunction. 4.Allergy to dexmedetomidine, propofol, opioids, or other anesthetic medications. 5.Long-term use of sedatives or analgesics, or a history of substance abuse. 6.Pregnant or lactating women. 7.Intraoperative conversion to a different surgical procedure due to changes in clinical condition, or inability to complete continuous Intraoperative Neuromonitoring (IONM). 8.Poor compliance, rendering the patient unable to cooperate with postoperative follow-up assessments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anesthetic Dosage;The incidence of recurrent laryngeal nerve (RLN) palsy 72 hours after surgery;Intraoperative vital signs and drug dosage; | — |
Secondary
| Measure | Time frame |
|---|---|
| Amplitude attenuation rate of Electromyography (EMG) signals;Demographics and Medical History;GRBAS score / VHI-10 score; | — |
Countries
China
Contacts
Public ContactCai Qiang
The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology
Outcome results
None listed